Phase 3 Trials
-
{
- All
- News
-
Bharat Biotech Seeks Approval For Phase 3 Trial Of Intranasal Shots As Boosters
Bharat Biotech has sought the Drug Controller General of India's approval to conduct phase-3 trials of its intranasal vaccine (BBV154) against Covid to be used as a booster dose, sources said on Monday.
-
Covaxin Phase 3 Trial Data Shared With Expert Panel Which Meets Today
Bharat Biotech has submitted Phase III trial data for the Covaxin coronavirus vaccine to the DCGI (Drug Controller General of India), whose SEC (subject expert committee) is expected to meet later today - likely around noon.
-
Bharat Biotech Enrols Over 25,000 Volunteers For Covaxin Phase 3 Trial
Bharat Biotech has enrolled 25,800 volunteers for phase 3 clinical trials of its COVID-19 vaccine, the company said today. The maker of Covaxin is one of the two firms cleared by the government to deploy their product for mass inoculation in the country. The other is Oxford-AstraZeneca's Covishield manufactured by the Serum Institute of India.
-
Covaxin Crosses Half-Way Mark In Phase-3 Trials, Says Bharat Biotech
India's first and only phase III trial of a COVID-19 vaccine has crossed 13,000 subjects - the half-way mark - and proceeding successfully across multiple sites in India, Bharat Biotech, the maker of the inoculant Covaxin, announced today. The trials in the first and second phases had led to promising results.
-
50,000 People Globally Part Of Phase 3 Trial Of Chinese COVID-19 Vaccine
Around 50,000 people, across a number of countries, are participating in phase 3 clinical trials of a COVID vaccine developed by the China National Biotec Group (CNBG), the company said on Saturday in a press release.
-
Bharat Biotech Seeks Approval For Phase 3 Trial Of Intranasal Shots As Boosters
Bharat Biotech has sought the Drug Controller General of India's approval to conduct phase-3 trials of its intranasal vaccine (BBV154) against Covid to be used as a booster dose, sources said on Monday.
-
Covaxin Phase 3 Trial Data Shared With Expert Panel Which Meets Today
Bharat Biotech has submitted Phase III trial data for the Covaxin coronavirus vaccine to the DCGI (Drug Controller General of India), whose SEC (subject expert committee) is expected to meet later today - likely around noon.
-
Bharat Biotech Enrols Over 25,000 Volunteers For Covaxin Phase 3 Trial
Bharat Biotech has enrolled 25,800 volunteers for phase 3 clinical trials of its COVID-19 vaccine, the company said today. The maker of Covaxin is one of the two firms cleared by the government to deploy their product for mass inoculation in the country. The other is Oxford-AstraZeneca's Covishield manufactured by the Serum Institute of India.
-
Covaxin Crosses Half-Way Mark In Phase-3 Trials, Says Bharat Biotech
India's first and only phase III trial of a COVID-19 vaccine has crossed 13,000 subjects - the half-way mark - and proceeding successfully across multiple sites in India, Bharat Biotech, the maker of the inoculant Covaxin, announced today. The trials in the first and second phases had led to promising results.
-
50,000 People Globally Part Of Phase 3 Trial Of Chinese COVID-19 Vaccine
Around 50,000 people, across a number of countries, are participating in phase 3 clinical trials of a COVID vaccine developed by the China National Biotec Group (CNBG), the company said on Saturday in a press release.
